Please wait while the formulary information is being retrieved.
REBYOTA (fecal microbiota, live-jslm)
- recurrent Clostridioides difficile infection
150 mL enema
- Insert 150 milliliters by rectal route once
Default screening record
- Insert 150 milliliters by rectal route once
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- No disease contraindications
REBYOTA (fecal microbiota, live-jslm)
- recurrent Clostridioides difficile infection
- None
- Acute abdominal pain
- Diarrhea
More Frequent
Severe
Less Severe
- None
- Abdominal distension
- Flatulence
- Nausea
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Fecal microbiota, live - jslm
Safety and efficacy not established age < 18 years.
- 1 Day – 18 Years
- Safety and efficacy not established age < 18 years.
Fecal Microbiota, Live-jslm
- Severity Level:
2
- Additional Notes: Drug not absorbed systemically after rectal administration
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Fecal Microbiota, Live-jslm
Not absorbed systemically after rectal admin; infant exposure not expected
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Not absorbed systemically after rectal admin; infant exposure not expected |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Recurrent clostridioides difficile infection | |
| A04.71 | Enterocolitis due to clostridium difficile, recurrent |
| 0-9 | A-Z |
|---|---|
| A04.71 | Enterocolitis due to clostridium difficile, recurrent |
Formulary Reference Tool